Search clinical trials for: LYS006

Total 37 results

Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

Inflammatory Acne

Germany, United States, Hungary, France, Czechia, Netherlands
Novartis Pharmaceuticals

Terminated

Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

Colitis, Ulcerative

Russian Federation, Czechia, Bulgaria, Germany, Poland, Slovakia
Novartis Pharmaceuticals

Terminated

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NEXSCOT)

Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Germany, Argentina
Lexeo Therapeutics

Recruiting

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Friedreich Ataxia | Cardiomyopathy, Secondary

United States, Canada
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
Maruho Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Cutaneous Common Warts

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Herpes Zoster

Australia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

SARS-CoV-2

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

SARS-CoV-2

China
Guangzhou Patronus Biotech Co., Ltd.
Afﬁliated Hospital of North Sichuan Medical College; Yantai Patronus Biotech...

Active, not recruiting

The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

COVID-19 | Vaccine Reaction

China
Cytos Biotechnology AG

Completed

Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

Essential Hypertension
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Eyevensys

Completed

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU) (ELECTRO)

Non-infectious Uveitis

United States
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001

COVID-19
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University; Shanghai Longyao...

Recruiting

An Evaluation of LY007 Cell Injection for r/r B-NHL (r/r B-NHL)

B-NHL

China
Shanghai Longyao Biotechnology Inc., Ltd.
The First Affiliated Hospital with Nanjing Medical University; Ruijin Hospital

Recruiting

An Evaluation of LY007 Cell Injection for r/r B-NHL (r/r B-NHL)

B-NHL

China
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

The Phase Ⅱ/Ⅲ Trial of LYB001

COVID-19
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001

COVID-19
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
Cytos Biotechnology AG

Completed

Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension

Hypertension

Switzerland, Germany
Luye Pharma Group Ltd.
Shandong Boan Biotechnology Co., Ltd

Unknown

A Study to Evaluate the Denosumab in Healthy Adults

Healthy Adults

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Terminated

Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Recruiting

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Postmenopausal Osteoporosis

China
Jiangsu Province Centers for Disease Control and...

Not yet recruiting

Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults

COVID-19

China
Zhongnan Hospital

Recruiting

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

SARS-CoV-2 | Safety | Immunotoxicity

China
Luye Pharma Group Ltd.
Parexel

Completed

A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

Healthy

Germany
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd

Active, not recruiting

A Study to Evaluate LY06006 and Prolia in Healthy Adults

Healthy Adults

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Maruho Co., Ltd.

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Cutaneous Common Warts

United States
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (Hi-CHOP)

Diffuse Large B-cell Lymphoma
Intech Biopharm Ltd.

Completed

Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers

Asthma

Taiwan

Search clinical trials for: LYS006

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations